Sotatercept is a Fusion Protein owned by Merck & Co, and is involved in 18 clinical trials, of which 11 were completed, 6 are ongoing, and 1 is planned.

Sotatercept (ACE-011) binds to a number of TGF beta superfamily ligands including activin A, activin B, growth differentiation factor-11 (GDF-11) and bone morphogenetic protein-10 (BMP-10). Sotatercept increases hemoglobin levels and RBCs in humans by targeting signaling by the transforming growth factor beta (TGF-beta) superfamily. The drug candidate stimulates increase hemoglobin/hematocrit levels.

The revenue for Sotatercept is expected to reach a total of $20.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sotatercept NPV Report.

Sotatercept was originated by Acceleron Pharma and is currently owned by Merck & Co.

Sotatercept Overview

Sotatercept (ACE-011) is under development for the treatment of anemia in patients with myelofibrosis, beta-thalassemia,  and pulmonary arterial hypertension. The drug candidate is administered subcutaneously and intravenously. Sotatercept is a dimeric fusion protein containing the extracellular domain of the activin receptor 2A (ACVR2A) fused to the Fc domain of human IgG1. It was also under development for the treatment of chemotherapy induced anemia (CIA), end stage renal disease (ESRD), solid tumor, osteoporosis and renal anemia in patients with chronic kidney disease on hemodialysis, multiple myeloma, metabolic bone disorders,Diamond-Blackfan anemia (inherited erythroblastopenia),  myelodysplastic syndrome and sickle cell disease.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Sotatercept

Report Segments
  • Innovator
Drug Name
  • Sotatercept
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Musculoskeletal Disorders
  • Oncology
  • Toxicology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.